<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2017-2-62-67</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-1007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ВНЕЗАПНАЯ СМЕРТЬ ПРИ ГИПЕРТРОФИЧЕСКОЙ КАРДИОМИОПАТИИ: ПОИСК НОВЫХ ФАКТОРОВ РИСКА</article-title><trans-title-group xml:lang="en"><trans-title>SUDDEN DEATH IN HYPERTROPHIC CARDIOMYOPATHY: SEARCH FOR NEW RISK FACTORS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0310-0771</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крылова</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Krylova</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент, кафедра общей терапии ФДПО</p></bio><email xlink:type="simple">krylova_n@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалевская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalevskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-кардиолог</p></bio><email xlink:type="simple">tolyaaa@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Потешкина</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Poteshkina</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>профессор, зав. кафедрой общей терапии ФДПО</p></bio><email xlink:type="simple">nat-pa@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демкина</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Demkina</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры общей терапии ФДПО</p></bio><email xlink:type="simple">ademkina@bk.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хашиева</surname><given-names>Ф. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Khashieva</surname><given-names>F. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры общей терапии ФДПО</p></bio><email xlink:type="simple">hawif@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва; &#13;
ГБУЗ ГКБ № 52 Департамента здравоохранения Москвы, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow; &#13;
CCH № 52 of Department of Health, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва; &#13;
ГБУЗ ГКБ № 52 Департамента здравоохранения Москвы, Москва&#13;
ФГБОУ ВО "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова", ГБУЗ ГКБ № 52 ДЗМ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow; &#13;
CCH № 52 of Department of Health, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>27</day><month>02</month><year>2017</year></pub-date><volume>0</volume><issue>2</issue><fpage>62</fpage><lpage>67</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Крылова Н.С., Ковалевская Е.А., Потешкина Н.Г., Демкина А.Е., Хашиева Ф.М., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Крылова Н.С., Ковалевская Е.А., Потешкина Н.Г., Демкина А.Е., Хашиева Ф.М.</copyright-holder><copyright-holder xml:lang="en">Krylova N.S., Kovalevskaya E.A., Poteshkina N.G., Demkina A.E., Khashieva F.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/1007">https://russjcardiol.elpub.ru/jour/article/view/1007</self-uri><abstract><p>Несмотря на разработанные алгоритмы стратификации риска внезапной сердечной смерти (ВСС) среди больных гипертрофической кардиомиопатией (ГКМП) встречаются случаи ВСС при отсутствии общепризнанных факторов риска. Проблема предупреждения ВСС при данной патологии не теряет своей актуальности.</p><sec><title>Цель исследования</title><p>Цель исследования: Изучить факторы риска ВСС у больных ГКМП.</p></sec><sec><title>Материал и методы</title><p>Материал и методы: На протяжении 14 лет обследовано 198 больных ГКМП (средний возраст -  60,0±13,8 лет, 105 мужчин) с проведением ЭКГ, ЭхоКГ, ХМ ЭКГ, велоэргометрии. За 14 лет умерло 15 пациентов. ВСС установлена в 7 случаях, у двоих больных - с успешной реанимацией.</p></sec><sec><title>Результаты</title><p>Результаты: У больных ГКМП выявлена взаимосвязь между ВСС и следующими клинико-инструментальными параметрами: возрастом (r=-0,19, p=0,015, обмороками в анамнезе (r=0,17, p=0,03), высокой скоростью кровотока в выносящем тракте ЛЖ при физической нагрузке (ФН) (VmaxВТЛЖ) (r=0,3, p=0,04), низкой толерантностью к ФН (r=-0,34, p=0,009), неадекватной реакцией АД (НРАД) при ФН (r=0,36, p=0,00001), высокой минимальной ЧСС при ХМ ЭКГ (r=0,26, p=0,01). При применении бинарной логистической регрессии с включением наиболее значимых предикторов получена модель для прогнозирования ВСС у больных ГКМП:</p><p>ВСС=22,28хНРАД-6,9хПродолжительностьФН+12,5хVmaxВТЛЖ+0,32хМинЧСС-0,4478хВозраст-14,7</p><p>Если полученный результат больше 0 – у больного имеется высокий риск ВСС. При отрицательном значении – риск ВСС минимален.</p><p>Значение χ2 для предложенной модели составило 19,3 (p=0,002).</p></sec><sec><title>Выводы</title><p>Выводы: Помимо общепризнанных (возраст, обмороки, выраженность обструкции ВТЛЖ, НРАД при ФН), установлены дополнительные факторы высокого риска ВСС у больных ГКМП: низкая толерантность к ФН и высокие значения минимальной ЧСС при ХМ-ЭКГ. Предложена математическая модель, позволяющая на основании возраста больного, наличия НРАД при ФН, толерантности к ФН, максимальной скорости кровотока в ВТЛЖ при ФН, а также минимальной ЧСС по данным ХМ-ЭКГ выявлять больных с высоким риском ВСС.</p></sec></abstract><trans-abstract xml:lang="en"><p>Regardless the developed algorithms for risk stratification in sudden cardiac death (SCD) among patients with hypertrophy cardiomyopathy (HCM) there are SCD cases with no common risk factors. The issue for prediction of SCD in this pathology does not lose its importance.</p><sec><title>Aim</title><p>Aim. To study the risk factors for SCD in HCM patients.</p></sec><sec><title>Material and methods</title><p>Material and methods. During 14 years, 198 HCM patients studied (mean age — 60,0±13,8 y.o., 105 males) with ECG, EchoCG, Holter ECG, veloergometry done. During 14 years, 15 died. There was 7 SCD cases with 2 successful resuscitations.</p></sec><sec><title>Results</title><p>Results. In HCM patients there was relation of SCD with the following clinical and instrumental parameters: age (r=-0,19, p=0,015), syncopes in anamnesis (r=0,17, p=0,03), high flow velocity in outflow tract of the left ventricle (LV) in exertion (Ex) (VmaxLVOT) (r=0,3, p=0,04), low Ex tolerance (r=-0,34, p=0,009), abnormal Ex response of blood pressure (ABPR) (r=0,36, p=0,00001), high minimal heart rate (HR) on Holter ECG (r=0,26, p=0,01). Applying the binary logistic regression with inclusion of the most significant predictors, the model was formulated for SCD prediction in HCM patients: SCD=22,28хABPR-6,9хEx Duration+12,5хVmaxLVOT+0,32хMinHR-0,4478хAge-14,7 If the result of equation more than 0 — the patient has high risk of SCD. In negative — SCD risk is minimal. Value of χ2 for the proposed equation is 19,3 (p=0,002).</p></sec><sec><title>Conclusion</title><p>Conclusion. Regardless the common (age, syncopes, severity of LVOT obstruction, ABPR in Ex) there are additional SCD risk factors in HCM patients: low Ex tolerance and high minimal HR on Holter ECG. the mathematic model proposed, making to, based on the age of patient and presence of ABPR in Ex, Ex tolerance, maximal flow velocity in LVOT in Ex, as minimal HR by Holter ECG, to reveal patients with high risk of SCD.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гипертрофическая кардиомиопатия</kwd><kwd>внезапная сердечная смерть</kwd><kwd>факторы риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertrophic cardiomyopathy</kwd><kwd>sudden cardiac death</kwd><kwd>risk factors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-16.</mixed-citation><mixed-citation xml:lang="en">Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-16.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gersh B.J., Maron B.J., Bonow R.O. et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation – 2011 – Vol.124 – P. 783 - 831.</mixed-citation><mixed-citation xml:lang="en">Gersh B.J., Maron B.J., Bonow R.O. et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation – 2011 – Vol.124 – P. 783 - 831.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal. 2014. P. 2733-2779.</mixed-citation><mixed-citation xml:lang="en">Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal. 2014. P. 2733-2779.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">O’Mahony C, Jichi F, Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20.</mixed-citation><mixed-citation xml:lang="en">O’Mahony C, Jichi F, Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dubourg O, Charron P, Sirol M et al. Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016. Presse Med. 2016 Oct;45(10):903-910.</mixed-citation><mixed-citation xml:lang="en">Dubourg O, Charron P, Sirol M et al. Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016. Presse Med. 2016 Oct;45(10):903-910.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Priori SG, Blomström-Lundqvist C, Mazzanti A et all. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal doi:10.1093/eurheartj/ehv316.</mixed-citation><mixed-citation xml:lang="en">Priori SG, Blomström-Lundqvist C, Mazzanti A et all. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal doi:10.1093/eurheartj/ehv316.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harmon KG, Asif IM, Maleszewski JJ, Incidence and Etiology of Sudden Cardiac Arrest and Death in High School Athletes in the United States. Mayo Clin Proc. 2016 Nov;91(11):1493-1502.</mixed-citation><mixed-citation xml:lang="en">Harmon KG, Asif IM, Maleszewski JJ, Incidence and Etiology of Sudden Cardiac Arrest and Death in High School Athletes in the United States. Mayo Clin Proc. 2016 Nov;91(11):1493-1502.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Maron BJ, Doerer JJ, Haas TS, et al: Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the U.S., 1980-2006. Circulation 119:1085, 2009.</mixed-citation><mixed-citation xml:lang="en">Maron BJ, Doerer JJ, Haas TS, et al: Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the U.S., 1980-2006. Circulation 119:1085, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Komissarova SM, Melnikova OP, Gevorkyan TT. et al. Prediction of sudden cardiac death at hypertrophic cardiomyopathy: high risk patients identification. Journal Heart Failure. 2013 T. 14, №6(80). P. 322-328. (Комиссарова С.М., Мельникова О.П., Геворкян Т.Т. с соавт. Прогнозирование внезапной сердечной смерти при гипертрофической кардиомиопатии: идентификация пациентов высокого риска. Журнал сердечная недостаточность. 2013. Т. 14. № 6(80). С. 322-328).</mixed-citation><mixed-citation xml:lang="en">Komissarova SM, Melnikova OP, Gevorkyan TT. et al. Prediction of sudden cardiac death at hypertrophic cardiomyopathy: high risk patients identification. Journal Heart Failure. 2013 T. 14, №6(80). P. 322-328. (Комиссарова С.М., Мельникова О.П., Геворкян Т.Т. с соавт. Прогнозирование внезапной сердечной смерти при гипертрофической кардиомиопатии: идентификация пациентов высокого риска. Журнал сердечная недостаточность. 2013. Т. 14. № 6(80). С. 322-328).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Emoto R, Yokota Y, Miki T. et al. Prognosis of hypertrophic cardiomyopathy: echocardiographic and postmortem histopathologic study of 30 patients. J Cardiol. 1988 Sep;18(3):695-703.</mixed-citation><mixed-citation xml:lang="en">Emoto R, Yokota Y, Miki T. et al. Prognosis of hypertrophic cardiomyopathy: echocardiographic and postmortem histopathologic study of 30 patients. J Cardiol. 1988 Sep;18(3):695-703.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Belenkov YN., Privalova EV., Kaplunova VY. Hypertrophic cardiomyopathy: guideline for physicians. –M.: GEOTAR-Media, 2011.-392 p. (Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. Гипертрофическая кардиомиопатия: руководство для врачей. – М.: ГЭОТАР-Медиа, 2011. – 392 с.: ил.).</mixed-citation><mixed-citation xml:lang="en">Belenkov YN., Privalova EV., Kaplunova VY. Hypertrophic cardiomyopathy: guideline for physicians. –M.: GEOTAR-Media, 2011.-392 p. (Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. Гипертрофическая кардиомиопатия: руководство для врачей. – М.: ГЭОТАР-Медиа, 2011. – 392 с.: ил.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Peteiro J, Bouzas-Mosquera A, Fernandez X et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012 Feb;25(2):182-9.</mixed-citation><mixed-citation xml:lang="en">Peteiro J, Bouzas-Mosquera A, Fernandez X et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012 Feb;25(2):182-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">El-Saiedi SA, Seliem ZS, Esmail RI. Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients. Cardiol Young. 2013 Jul 29:1-7.</mixed-citation><mixed-citation xml:lang="en">El-Saiedi SA, Seliem ZS, Esmail RI. Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients. Cardiol Young. 2013 Jul 29:1-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kawasaki T, Sakai C, Harimoto K, et al. Holter monitoring and long-term prognosis in hypertrophic cardiomyopathy. Cardiology. 2012;122(1):44-54.</mixed-citation><mixed-citation xml:lang="en">Kawasaki T, Sakai C, Harimoto K, et al. Holter monitoring and long-term prognosis in hypertrophic cardiomyopathy. Cardiology. 2012;122(1):44-54.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
